Study Published in Neurology Shows Chronic Epilepsy Associated with Marker of Cardiac Electrical Instability

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

The publication of a new study in Neurology, suggests that chronic epilepsy may be associated with key measures of sudden cardiac death risk.1 This is the third in a series of studies1-3 to evaluate cardiac electrical instability in patients with chronic epilepsy but the first to compare the cardiac impact of the disease among patients with chronic epilepsy to those who are newly diagnosed. The news was announced today by LivaNova PLC.

The study in Neurology evaluated established markers of sudden cardiac death risk, T-wave alternans (TWA) and heart rate variability (HRV), in patients with chronic epilepsy compared to patients with newly diagnosed epilepsy. Using data recorded on ambulatory electrocardiographic monitors, the investigators assessed whether cardiac electrical instability indicated by TWA and abnormal autonomic tone measured by HRV result from recurrent seizures. Results from the analysis showed that chronic epilepsy is associated with higher TWA levels and simultaneously with lower HRV, suggesting autonomic dysfunction or higher sympathetic tone.

“This study provides evidence indicating that, over time, some people with epilepsy may become predisposed to potentially serious heart rhythm abnormalities, due either to the effect of recurrent seizures, antiepileptic medications or other influences on the heart,” said Dr. Trudy Pang, lead study author and Assistant Professor of Neurology at Harvard Medical School. “Further work is needed to understand better the risks and the cause(s), so that we can develop more effective treatment options.”

Two previous studies in this series have shown that vagus nerve stimulation was associated with improvement in HRV and cardiac vagal tone and reduction in TWA in patients with epilepsy,2,3 making it a potential treatment for further study.

“This latest study published in Neurology further contributes to our understanding of the risk factors for sudden cardiac death in patients with epilepsy.4 The prior two studies in the series2,3 evaluated the potential for Vagus Nerve Stimulation Therapy® or VNS Therapy to reduce T-wave alternans, a well-established marker of cardiac electrical instability, in patients with drug-resistant epilepsy,” said Bryan Olin, study co-author and Senior Vice President of Clinical, Quality and Regulatory Affairs at LivaNova. “The clinical impact of this effect in terms of reducing the rate of sudden cardiac death in patients with epilepsy remains to be studied. However, results from this study may also guide development of medical therapy for both seizure reduction and cardiac protection in patients with epilepsy.”

The LivaNova VNS Therapy System is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children.


Pang TD, Nearing, BD, Krishnamurthy KB, Olin B, Schachter SC, Verrier RL. Cardiac electrical instability in newly diagnosed/chronic epilepsy tracked by Holter and ECG patch. Neurology 2019; 93: 450-458.


Schomer AC, Nearing BD, Schachter SC, Verrier RL. Vagus nerve stimulation reduces cardiac electrical instability assessed by quantitative T-wave alternans analysis in patients with drug-resistant focal epilepsy. Epilepsia 2014; 55: 1996-2002.


Verrier RL, Nearing BD, Olin B, Boon P, Schachter SC. Baseline elevation and reduction in cardiac electrical instability assessed by quantitative T-wave alternans in patients with drug-resistant epilepsy treated with vagus nerve stimulation in the AspireSR E-36 trial. Epilepsy Behav 2016; 62: 85-89.


Bardai A, Lamberts RJ, Blom MT, et al. Epilepsy is a risk factor for sudden cardiac arrest in the general population. PLoS One 2012;7:e42749.



Subscribe to Medical Device News Magazine here.

Related Articles